Erlotinib Hydrochloride
Phase 2CompletedDevelopment Stage
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Adult Acute Promyelocytic Leukemia With PML-RARA, Alkylating Agent-Related Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia
May 16, 2013 → Oct 25, 2018
About Erlotinib Hydrochloride
Erlotinib Hydrochloride is a phase 2 stage product being developed by Astellas Pharma for Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01664897. Target conditions include Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01664897 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome